Investing in SomaLogic
Interested in potential investment opportunities?
SomaLogic Business News
SomaLogic announces new phase of partnership with NEC Solution Innovators
Today SomaLogic, Inc. announced an enhanced collaboration with NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, that builds on the companies’ ten-year partnership by bringing new clinical tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese population.
SomaLogic releases new SomaSignal™ tests for NASH and NAFLD research
SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.
SomaScan proteomic technology is now broadly available to COVID-19 researchers and drug developers to expand and accelerate response to the pandemic
SomaLogic today launched a new initiative to deploy their proteomic technology against the coronavirus pandemic. The company is making its proprietary SomaScan® Assay available to biopharma companies, academic medical investigators, and government entities working on COVID-19/SARS-CoV-2 infection under simplified terms, with data from non-pharma studies to be shared rapidly and widely.
SomaLogic adds three new SomaSignal™ tests to its current offerings
SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
Blood test beats traditional predictors of multiple disease risks
Proteins in our blood could in future help provide a comprehensive “Liquid Health Check,” assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at SomaLogic, the University of California, San Francisco and Cambridge University in the UK, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict multiple disease risks.
SomaLogic announces three new appointments to board of directors
SomaLogic, a privately held precision health information company, announced today that it has appointed Anne Margulies, Harvard University Vice President and Chief Information Officer, Franck J. Moison, former Vice Chairman of Colgate-Palmolive, and private investor Richard “Rick” Post to its board of directors.
SomaLogic significantly expands key strategic collaboration with Novartis
SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.
Patrick Terry announced as first Chief Commercial Officer of SomaLogic
SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
SomaLogic launches its first SomaSignal™ tests in select medical practices
SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
For all the latest SomaLogic news, please visit our News and Events page.